Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database

Funatogawa, Takashi; Narita, Yusuke; Tamura, Aya; Mii, Kazuma; Sugitani, Yasuo; Uchida, Tomoaki

doi:10.1093/mr/roab111

Cited by 3 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MMF doses used in these studies typically ranged from 1000 to 3000 mg/day. Furthermore, in a survey using Japanese hospital billing data, the most common initial and maximum dose of MMF for patients with SSc‐ILD was 1000 mg/day 12 . Based on these results, we adjusted the MMF dose to 1000 mg/day for the treatment of CIP.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, in a survey using Japanese hospital billing data, the most common initial and maximum dose of MMF for patients with SSc‐ILD was 1000 mg/day. 12 Based on these results, we adjusted the MMF dose to 1000 mg/day for the treatment of CIP. However, determining the appropriate usage and dosage of MMF for CIP will require further study.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effective treatment of steroid‐resistant immune checkpoint inhibitor pneumonitis with mycophenolate mofetil

Shioiri,

Kikuchi,

Matsumoto

et al. 2024

Respirology Case Reports

View full text Add to dashboard Cite

Insufficient evidence is available for treating steroid‐resistant immune checkpoint inhibitor pneumonitis (CIP). Although guidelines recommend the use of immunosuppressants, the efficacy of mycophenolate mofetil (MMF) has not been sufficiently verified. We report two cases of steroid‐resistant CIP treated with MMF. Both patients responded to initial treatment with prednisolone (PSL), but the CIP flared up repeatedly as the steroids were gradually tapered off. Upon receiving MMF in addition to PSL, their subjective symptoms improved, and the shadows gradually disappeared, allowing for a reduction in the steroid dose. Ultimately, no CIP recurrence was observed despite discontinuing PSL and MMF. Both cases were completely resolved by treatment with MMF. This indicates that MMF may be effective in treating steroid‐resistant CIP. In the future, the effects and safety of MMF should be investigated in large‐scale clinical trials targeting patients with steroid‐resistant CIP.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Effective treatment of steroid‐resistant immune checkpoint inhibitor pneumonitis with mycophenolate mofetil

Shioiri,

Kikuchi,

Matsumoto

et al. 2024

Respirology Case Reports

View full text Add to dashboard Cite

show abstract

Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database

Narita¹,

Funatogawa²,

Mii³

et al. 2022

Modern Rheumatology

View full text Add to dashboard Cite

Objectives Limited information is available on the use of biologics in patients with systemic sclerosis (SSc) or SSc-associated interstitial lung disease (SSc-ILD) in Japan. The types of biologics, treatment duration, treatment prior to biologics, concomitant treatment, and characteristics of patients receiving biologics were investigated. Method We used a Japanese hospital claims database provided by Medical Data Vision Co. (2008–2021). Results In the database, 1,186 of 34,207 SSc patients (3.5%) and 620 of 12,303 SSc-ILD patients (5.0%) received anti-interleukin-6 (anti-IL-6) drugs, anti-tumor necrosis factor (anti-TNF) drugs, abatacept, or rituximab. The most common were anti-IL-6 drugs (used in 35.5% of SSc patients and 38.5% of SSc-ILD patients [tocilizumab, 34.5% and 36.6%]), followed by anti-TNF drugs (31.3% and 26.5% [etanercept, 10.5% and 9.0%; others, <8%]), abatacept (17.5% and 20.6%), and rituximab (15.7% and 14.4%). Among SSc and SSc-ILD patients treated with anti-IL-6 drugs, anti-TNF drugs, or abatacept, the most common immunosuppressive drugs prior to initiation of biologics were methotrexate and tacrolimus. Approximately half of patients receiving anti-IL-6 drugs, anti-TNF drugs, or abatacept continued treatment beyond 1 year. Conclusions Our study indicates that off-label biologics have been used in a certain number of SSc or SSc-ILD patients in Japan, with tocilizumab the most common.

show abstract

Lung Involvement in Systemic Sclerosis—From Pathogenesis to Prediction

Kaouri,

Bakopoulou,

Padjen

et al. 2024

Sclerosis

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a rare, multifactorial autoimmune disease characterized by widespread vascular damage and fibrosis. Pulmonary involvement is a significant manifestation of SSc, contributing to considerable morbidity and mortality. Therefore, identifying reliable biomarkers is of the utmost importance. This review explores emerging biomarkers to enhance diagnostic accuracy, prognostic assessment, and disease monitoring in SSc lung involvement. We discuss recent findings in immunological biomarkers, inflammatory indicators, and other parameters that can function as potential diagnostic and prognostic tools. A comprehensive understanding of these biomarkers could result in earlier and more accurate detection of pulmonary complications in SSc, aiding in timely intervention. Furthermore, we explore the advances in disease monitoring through innovative biomarkers, focusing on their roles in disease activity and treatment response. Integrating these novel biomarkers into current clinical practice and therapeutic protocols through clinical trials can revolutionize the management of SSc-related lung disease, ultimately improving patient outcomes and quality of life.

show abstract

Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database

Cited by 3 publications

References 23 publications

Effective treatment of steroid‐resistant immune checkpoint inhibitor pneumonitis with mycophenolate mofetil

Effective treatment of steroid‐resistant immune checkpoint inhibitor pneumonitis with mycophenolate mofetil

Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database

Lung Involvement in Systemic Sclerosis—From Pathogenesis to Prediction

Contact Info

Product

Resources

About